$GYGY

Game Your Game Inc. (GYGY): Unregistered Sales of Equity Securities

Game Your Game Inc. (GYGY) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in the registration statement on Form S-1 (File No. 333-296763) (as amended, the “Registration Statement”) relating to the listing (the “Direct Listing”) of the shares of common stock, par value $0.001 per

Original reporting
Published Jul 30, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GYGY
Neutral
medium confidence
Mentioned
$GYGY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GYGYNeutralMed
01

Why it matters

This 8-K confirms the second closing on July 30, 2026, issuing 8,000 Series A preferred shares for $8M and setting conversion terms, preferred return, and resale registration obligations with potential cash fees.

02

Market read

The market gets a concrete, completed financing datapoint (size, tranche, conversion framework) that can drive dilution and registration overhang expectations.

03

What to watch

Traders should model the 9.99% beneficial ownership cap and the registration-fee schedule, since failure to register resale could create additional cash outflows or renegotiation risk.

Relevance 5/10Novelty 8/10Timing: filed July 30, 2026, confirming the second closing and $8M issuance

Background

GYGY previously disclosed a direct listing tied to a Securities Purchase Agreement with Streeterville Capital for up to $40M of Series A convertible preferred.

Company-level read

Ticker impact

$GYGYNeutralMedium confidence
Context

Game Your Game disclosed a second closing under its $40M preferred purchase agreement, issuing 8,000 Series A convertible preferred shares for $8M.

Expected impact

Near-term pressure is plausible due to dilution/conversion overhang, but direction depends on how the market prices the conversion price, floor, and registration-fee risk.

Evidence & confidence

The 8-K is a primary disclosure of a completed financing closing, including conversion price ($8.00 initially, floor $4.00), 9.99% beneficial ownership cap, and potential cash fees if resale registration is not effective.

Market effects

Adds another example of small-cap equity-linked financing via convertible preferred with resale-registration requirements, which can weigh on sentiment for similar issuers.

Limited, primarily affects Nasdaq-listed microcap liquidity and dilution expectations.

Low, no cross-border deal or macro linkage disclosed.

Counterpoint

If the conversion price and floor are favorable versus the current market price, the overhang may be less severe than typical dilutive financings.

Key entities

  • Game Your Game, Inc.

    Nasdaq-listed company filing the 8-K about unregistered sales of equity securities via Series A convertible preferred.

  • Streeterville Capital, LLC

    Purchaser under the Preferred Purchase Agreement, receiving 8,000 Series A preferred shares at the second closing.

Related articles

$CLVTHighAI 8/10

CLARIVATE PLC (CLVT): Other Events

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities LONDON, September 23, 2026: Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yi

$VMed

VISA INC. (V): Other Events

VISA INC. (V) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 18, 2026, Visa Inc. (the “Company”) authorized the deposit of $405 million into the U.S. litigation escrow account previously established under the Company’s U.S. retrospective responsibility plan (the “Plan”). Under the terms of the Plan, whe

$GOSSMedAI 8/10

Gossamer Bio, Inc. (GOSS): Other Events

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

$EVMNMedAI 9/10

Evommune, Inc. (EVMN): Regulation FD Disclosure

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Palo Alto, Calif., and New York, September 23, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical

$LGVNMedAI 8/10

Longeveron Inc. (LGVN): Other Events

Longeveron Inc. (LGVN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) ------------------- Company Announces Exploration of All Options to Maximize Shareholder Value ● Th